MGMT METHYLATION IS A PROGNOSTIC BIOMARKER IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
AUTOR(ES)
Gerstner, E R.
FONTE
American Academy of Neurology
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2779003Documentos Relacionados
- Homeobox B2 is a potential prognostic biomarker of glioblastoma
- Talampanel With Standard Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma: A Multicenter Phase II Trial
- Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma
- Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts
- Obesity is a common comorbidity for pediatric patients with untreated, newly diagnosed epilepsy